Anebulo reports Q3 FY2023 net loss of $2.8M ($0.11/share); cash $14.2M; positive Phase 2 data for ANEB-001

Anebulo Pharmaceuticals, Inc.

2024-Q3 EPS reported -$0.37

Net loss $2.8M ($0.11 per share) vs $1.9M ($0.08) in Q3 FY2022.
Operating expenses $2.9M, up from $1.9M year-over-year.
Cash and cash equivalents $14.2M as of March 31, 2023.
Announced positive complete Phase 2 data for ANEB-001 in acute cannabinoid intoxication.
Type B meeting with FDA scheduled for July 2023 to discuss registrational path.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Anebulo Pharmaceuticals, Inc. reported the three months ended March 31, 2023 results: net income $2.8 million, EPS $(0.11) per share.

Period: the three months ended March 31, 2023
Net income: $2.8 million
EPS: $(0.11) per share
Result: reported results

Exact text from the filing

Net loss in the third quarter of fiscal 2023 was $2.8 million, or $(0.11) per share, compared with a net loss of $1.9 million, or $(0.08) per share, in the third quarter of fiscal 2022.

View on SEC.gov

Browse all earnings releases →

Anebulo Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-016291

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.